Clinical Trial

Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma

Name: Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Gastric/Gastroesophageal Junction Adenocarcinoma — clinical trial record (NCT07148427)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A single-arm, Phase II clinical study protocol of Apatolimab Tovolimab in combination with regorafenib and chemotherapy as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma

Trial Details

NCT Number	NCT07148427
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Gastric/Gastroesophageal Junction Adenocarcinoma
Enrollment	40 participants
Start Date	2025-09-20
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2025-08-29